Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myelogenous leukemia cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients with acute myelogenous leukemia that has relapsed following previous treatment.

Timeline

Start

1997-10

Primary completion

2001-04

Completion

—

Drugs

Indications